Important Safety Information

  • The most common adverse reactions in clinical studies (≥ 3% of Aimovig-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig full Prescribing Information.


Indication

Aimovig is indicated for the preventive treatment of migraine in adults.
Mechanism of action graphic Mechanism of action graphic

Mechanism of Action

Aimovig selectively targets and blocks the CGRP-R, disrupting a key component of migraine pathophysiology.1-6

Aimovig™ (erenumab-aooe) SureClick® autoinjector visual Aimovig™ (erenumab-aooe) SureClick® autoinjector visual

Once-monthly dosing

Aimovig is available for once-monthly self-administration with the Aimovig SureClick® autoinjector.1

Aimovig Ally™ logo Aimovig Ally™ logo

Product support and resources

Aimovig Ally is committed to helping your patients start and stay on Aimovig as prescribed. Aimovig Ally offers a variety of tools to support patients during treatment.

Indication

Aimovig is indicated for the preventive treatment of migraine in adults.

Important Safety Information

Please see Aimovig full Prescribing Information.

References: 1. Aimovig™ (erenumab-aooe) prescribing information, Amgen. 2. Burstein R, Noseda R, Borsook D. Migraine: Multiple processes, complex pathophysiology. J Neurosci. 2015;35:6619-6629.
3. Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80:193-199. 4. Russo AF. Calcitonin gene-related peptide (CGRP): A new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-552. 5. Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356:223-231. 6. Vu T, Ma P, Chen JS, et al. Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy migraine subjects. Pharm Res. 2017;34:1784-1795.